P218 Safety and Chemoprotection in Controlled Human Malaria Infection

Phase 1, randomised, double-blind trial of P218 in malaria, sponsored by Medicines for Malaria Venture. Primary endpoints: Number of Treatment-Emergent Adverse Events at 9 days and Geometric Mean Time From PfSPZ Challenge to First Quantitative Polymerase Chain Reaction (qPCR) Outcome Equal or Greater Than 250 Asexual Parasites Per mL of Blood at 28 days. Started Nov 2018; status: completed.